[go: up one dir, main page]

HUE066662T2 - Súlyos atópiás dermatitisz kezelési módszerei egy il-4r inhibitor adagolásával - Google Patents

Súlyos atópiás dermatitisz kezelési módszerei egy il-4r inhibitor adagolásával

Info

Publication number
HUE066662T2
HUE066662T2 HUE17777145A HUE17777145A HUE066662T2 HU E066662 T2 HUE066662 T2 HU E066662T2 HU E17777145 A HUE17777145 A HU E17777145A HU E17777145 A HUE17777145 A HU E17777145A HU E066662 T2 HUE066662 T2 HU E066662T2
Authority
HU
Hungary
Prior art keywords
administering
inhibitor
methods
atopic dermatitis
treating severe
Prior art date
Application number
HUE17777145A
Other languages
English (en)
Inventor
Allen Radin
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59974890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE066662(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of HUE066662T2 publication Critical patent/HUE066662T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/247IL-4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HUE17777145A 2016-09-22 2017-09-21 Súlyos atópiás dermatitisz kezelési módszerei egy il-4r inhibitor adagolásával HUE066662T2 (hu)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662397988P 2016-09-22 2016-09-22
US201762442083P 2017-01-04 2017-01-04
US201762443819P 2017-01-09 2017-01-09
US201762445774P 2017-01-13 2017-01-13
US201762519896P 2017-06-15 2017-06-15
EP17306081 2017-08-18

Publications (1)

Publication Number Publication Date
HUE066662T2 true HUE066662T2 (hu) 2024-09-28

Family

ID=59974890

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17777145A HUE066662T2 (hu) 2016-09-22 2017-09-21 Súlyos atópiás dermatitisz kezelési módszerei egy il-4r inhibitor adagolásával

Country Status (13)

Country Link
US (1) US20220110999A1 (hu)
EP (2) EP3515465B1 (hu)
JP (3) JP7164530B2 (hu)
KR (3) KR20230006049A (hu)
CN (2) CN109963577B (hu)
AU (2) AU2017332732B2 (hu)
CA (1) CA3037499A1 (hu)
ES (1) ES2974376T3 (hu)
HU (1) HUE066662T2 (hu)
IL (2) IL310371A (hu)
MX (3) MX2019003235A (hu)
PL (1) PL3515465T3 (hu)
RU (1) RU2759630C2 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
RU2704999C2 (ru) 2014-02-28 2019-11-01 Ридженерон Фармасьютикалз, Инк. Способ лечения кожной инфекции путем введения антагониста il-4r
EP3506931B1 (en) 2016-09-01 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an il-4r antagonist
CN111514292B (zh) * 2018-12-25 2023-06-20 江苏荃信生物医药股份有限公司 抗人白介素4受体α单克隆抗体的制药用途
JP2022526738A (ja) 2019-03-21 2022-05-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アレルギーを治療するためのil-4/il-13経路阻害剤と形質細胞除去の組み合わせ
WO2021026203A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
MX2022001247A (es) 2019-08-05 2022-04-25 Regeneron Pharma Metodos para tratar dermatitis atopica mediante la administracion de un antagonista il-4r.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292665B1 (en) 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
US6896906B2 (en) * 2000-12-21 2005-05-24 Nektar Therapeutics Storage stable powder compositions of interleukin-4 receptor
MXPA06004853A (es) 2003-11-07 2006-07-06 Immunex Corp Anticuerpos que se aglutinan al receptor 4 de interleucina.
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
LT2769992T (lt) 2006-10-02 2021-04-12 Regeneron Pharmaceuticals, Inc. Didelio afiniškumo žmogaus antikūnai, atpažįstantys žmogaus il-4 receptorių
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
PL3354280T3 (pl) 2010-10-06 2021-02-08 Regeneron Pharmaceuticals, Inc. Stabilizowane preparaty zawierające przeciwciała przeciwko receptorowi interleukiny 4 (IL-4R)
EP4374919A3 (en) 2012-09-07 2024-08-21 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
TWI682781B (zh) * 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r

Also Published As

Publication number Publication date
CN109963577A (zh) 2019-07-02
EP3515465B1 (en) 2024-02-07
RU2019111921A (ru) 2020-10-22
RU2019111921A3 (hu) 2020-12-29
EP4345110A2 (en) 2024-04-03
IL265516B1 (en) 2024-02-01
MX2019003235A (es) 2019-07-08
AU2024203951A1 (en) 2024-07-04
JP2024174962A (ja) 2024-12-17
AU2017332732A1 (en) 2019-04-11
CN118203659A (zh) 2024-06-18
KR20230006049A (ko) 2023-01-10
KR20240146104A (ko) 2024-10-07
IL265516A (en) 2019-05-30
PL3515465T3 (pl) 2024-08-12
CN109963577B (zh) 2024-03-12
JP7164530B2 (ja) 2022-11-01
JP2019529560A (ja) 2019-10-17
CA3037499A1 (en) 2018-03-29
RU2759630C2 (ru) 2021-11-16
EP3515465A1 (en) 2019-07-31
IL310371A (en) 2024-03-01
MX2023014187A (es) 2024-01-16
AU2017332732B2 (en) 2024-03-14
EP4345110A3 (en) 2024-06-12
ES2974376T3 (es) 2024-06-27
US20220110999A1 (en) 2022-04-14
IL265516B2 (en) 2024-06-01
JP2022160685A (ja) 2022-10-19
MX2024011262A (es) 2024-09-23
KR20190053250A (ko) 2019-05-17

Similar Documents

Publication Publication Date Title
PT3515465T (pt) Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
SG11202009371WA (en) Methods for treating atopic dermatitis by administering an il-4r inhibitor
IL285201A (en) EZH2 inhibitors for the treatment of lymphoma
IL265516A (en) Methods for treating severe allergic dermatitis by administering an il-4r inhibitor
IL256056A (en) ezh2 inhibitors for the treatment of lymphoma
IL289930A (en) Methods for treating atopic dermatitis using an IL-4R antagonist
IL279308A (en) Methods for the treatment of heptidine-mediated disorders
PL3107575T3 (pl) Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
EP3171878A4 (en) Methods for treating paramyxoviruses
EP3268087A4 (en) METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
HK1244217A1 (zh) 用於治療蛋白質病的方法
EP3193865A4 (en) Methods for treating brain metastasis
EP3134120A4 (en) Compositions and methods for treating cytokine-related disorders
IL249475A0 (en) Methods for treating itching
ZA201600048B (en) Method for treating internal arcs
EP3091972A4 (en) Method of treating liver disorders
ZA201903005B (en) Methods and compositions for treating atopic dermatitis
AU2015305430B2 (en) Method for treating hyperhidrosis
EP3233121A4 (en) Methods for treating inflammatory arthritis
EP3139911A4 (en) Method of treating advanced non-alcoholic steatohepatitis
HK1257072A1 (zh) 治療多發性硬化的方法
EP3246432A4 (en) Method for treating parts
IL247290A0 (en) Methods of treating or preventing asthma by adding an il-4r antagonist
AU2015904770A0 (en) Compounds and methods for treating metabolic disorders